November 11, 2026 · The New England journal of medicine · DOI: 10.1056/NEJMoa2609762

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.

Listen to this summary

This phase 3 randomized, double-blind trial asked whether adding intismeran autogene, an individualized neoantigen mRNA vaccine, to pembrolizumab improves outcomes after complete resection of high-risk stage IIB–IV melanoma compared with pembrolizumab alone. Among 1,137 patients, intismeran plus pembrolizumab significantly improved recurrence-free survival (24-month rate 82.2% vs. 70.0%) and distant-metastasis-free survival (88.5% vs. 80.2%), with benefit emerging after about 6 months and no early separation. Grade 3 or higher adverse events were modestly more common with the combination (23.6% vs. 20.3%), and treatment-related deaths were rare (8 patients, 1.1%).

Georgina V Long, Muhammad A Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo S Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M Mehnert, Patrick A Ott, Reinhard Dummer, Paola Queirolo, Christoffer Gebhardt, Caroline Dutriaux, Carlos Rojas, Yuanbin Chen, Lisa M Tachiki, Ronnie Shapira-Frommer, Oliver Bechter, Ryan J Sullivan, Alexander M M Eggermont, Laureen S Ojalvo, Michelle Brown, Jinchun Zhang, Dmitri O Grebennik, Mizuho Fukunaga-Kalabis, Paolo A Ascierto, Michele Del Vecchio

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play